Mibavademab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Hypothalamic Amenorrhea (FHA)
Conditions
Functional Hypothalamic Amenorrhea (FHA)
Trial Timeline
Mar 31, 2026 → Dec 8, 2027
NCT ID
NCT07235917About Mibavademab
Mibavademab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Functional Hypothalamic Amenorrhea (FHA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07235917. Target conditions include Functional Hypothalamic Amenorrhea (FHA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07235917 | Phase 2 | Recruiting |
| NCT07220772 | Phase 3 | Recruiting |
| NCT06548100 | Phase 3 | Active |
Competing Products
20 competing products in Functional Hypothalamic Amenorrhea (FHA)